BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 157 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $232,000 | +96.6% | 18,428 | +153.7% | 0.01% | +100.0% |
| Q1 2022 | $118,000 | +321.4% | 7,265 | +266.7% | 0.00% | +300.0% |
| Q3 2021 | $28,000 | -40.4% | 1,981 | -57.1% | 0.00% | -50.0% |
| Q1 2021 | $47,000 | +46.9% | 4,618 | +8.2% | 0.00% | +100.0% |
| Q4 2020 | $32,000 | -5.9% | 4,268 | -40.6% | 0.00% | -75.0% |
| Q2 2020 | $34,000 | +466.7% | 7,184 | +160.5% | 0.00% | +33.3% |
| Q1 2020 | $6,000 | -33.3% | 2,758 | +8.0% | 0.00% | +50.0% |
| Q4 2019 | $9,000 | -55.0% | 2,554 | +1.9% | 0.00% | -75.0% |
| Q1 2019 | $20,000 | +900.0% | 2,507 | +1153.5% | 0.01% | +700.0% |
| Q4 2018 | $2,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |